You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Details for Patent: 10,702,536

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,702,536 protect, and when does it expire?

Patent 10,702,536 protects APTIOM and is included in one NDA.

This patent has seven patent family members in six countries.

Summary for Patent: 10,702,536

Title:	Methods of treatment of partial onset seizures using eslicarbazepine acetate
Abstract:	The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate.
Inventor(s):	de Almeida; Jose Luis (Arouca, PT), Soares da Silva; Patricio Manuel Vieira Ara (Oporto, PT)
Assignee:	BIAL-PORTELA & CA S.A. (S. Mamede Do Coronado, PT)
Application Number:	15/422,278
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 10,702,536

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-001	Nov 8, 2013	AB	RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF PARTIAL-ONSET SEIZURES	⤷ Try a Trial
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-002	Nov 8, 2013	AB	RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF PARTIAL-ONSET SEIZURES	⤷ Try a Trial
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-003	Nov 8, 2013	AB	RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF PARTIAL-ONSET SEIZURES	⤷ Try a Trial
Sumitomo Pharma Am	APTIOM	eslicarbazepine acetate	TABLET;ORAL	022416-004	Nov 8, 2013	AB	RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				TREATMENT OF PARTIAL-ONSET SEIZURES	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 10,702,536

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	055939	⤷ Try a Trial
Australia	2005331690	⤷ Try a Trial
Brazil	PI0520258	⤷ Try a Trial
Canada	2607427	⤷ Try a Trial
Mexico	2007013882	⤷ Try a Trial
Mexico	366496	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.